A session at the virtual 2021 American Academy of Pediatrics National Conference & Exhibition highlights menstrual disorders in adolescent girls.
Much like a person’s pulse rate, body temperature, respiration rate and blood pressure, menstruation can serve as a vital sign of a girl’s health and menstrual issues can indicate underlying health concerns. At the virtual 2021 American Academy of Pediatrics National Conference & Exhibition, Selma F. Witchel, MD, FAAP, professor of pediatrics at UPMC Children’s Hospital of Pittsburgh in Pennsylvania discussed the difference between normal and abnormal menses, the available toolbox, common irregular menses situations, and what to consider with menses in special populations.
The median age at menarche is 12.43 years. Normal menarche has a flow length of ≤7 days and typical product use is 3 to 6 pads or tampons a day. The cycle interval is irregular during the first gynecologic year; 21-45 days during the second gynecologic year; and 21-35 days from third gynecologic year until menopause. Signs of abnormal menses include menses lasting more than 7 days; initially regular menses becoming irregular; menses requiring pad/tampon changes every 1-2 hours and throughout the night; no menses by age 15 years with appropriate pubertal development; and no menses within 3 years of the onset of breast development.
Therapies available in the toolbox to use with menstrual disorders include combined oral contraceptives, the vaginal ring, depot medroxyprogesterone acetate, progestin-containing intrauterine devices, gonadotropin-releasing hormone (GnRH)-superagonists, and etronogestrel subnormal implants. Witchel noted that providers should be aware of whether treatments could impact bone mineral density during such a pivotal time, like combined oral contraceptives that have a mild negative impact or depot medroxyprogesterone acetate that has a significant adverse effect, or carry a risk of venous thromboembolism, such as combined oral contraceptives.
Witchel then discussed common irregular menstrual concerns including:
The session ended with Witchel discussing menstruation in adolescent girls with disabilities. She noted that menstrual management or suppression is often desired by this group. Providers should engage in shared decision-making when possible. Some physical disabilities may make some forms of menstrual hygiene more difficult or undesirable. Some medications may cause hyperprolactinemia and interactions may occur between some seizure medications and sex steroids. A hysterectomy is not considered appropriate management in this group. If it’s being considered as a last resort, Witchel recommended a consult with an ethics committee.
Reference
1. Witchel S. Evaluation and management of menstrual disorders in teens. American Academy of Pediatrics 2021 National Conference & Exhibition; virtual. Accessed October 8, 2021.
Unlocking HPV prevention: Insights from 2022 data on vaccination trends
May 14th 2024Explore the latest findings revealing vaccination rates among children aged 9 to 17 years, uncovering demographic disparities and highlighting the crucial role of vaccination in combating human papillomavirus infections and related health risks.
Read More
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More
Understanding pediatric STIs: Trends, management, and more
May 10th 2024Dive into the rising prevalence of sexually transmitted infections among adolescents and young adults, exploring educational gaps, vaccination rates, and the imperative need for open conversations between patients and health care providers to combat stigma and enhance preventive care.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More